Corneal axonal loss as an imaging biomarker of neurodegeneration in multiple sclerosis: a longitudinal study.
axonal loss
biomarker
corneal confocal microscopy
multiple sclerosis
neurodegeneration
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
03
2022
accepted:
23
07
2022
entrez:
13
2
2023
pubmed:
14
2
2023
medline:
14
2
2023
Statut:
epublish
Résumé
Resourceful endpoints of axonal loss are needed to predict the course of multiple sclerosis (MS). Corneal confocal microscopy (CCM) can detect axonal loss in patients with clinically isolated syndrome and established MS, which relates to neurological disability. To assess corneal axonal loss over time in relation to retinal atrophy, and neurological and radiological abnormalities in MS. Patients with relapsing-remitting (RRMS) ( In patients with RRMS compared with controls at baseline, CNFD ( Progressive corneal and retinal axonal loss was identified in patients with MS, especially those with more active disease. CCM may serve as an imaging biomarker of axonal loss in MS.
Sections du résumé
Background
UNASSIGNED
Resourceful endpoints of axonal loss are needed to predict the course of multiple sclerosis (MS). Corneal confocal microscopy (CCM) can detect axonal loss in patients with clinically isolated syndrome and established MS, which relates to neurological disability.
Objective
UNASSIGNED
To assess corneal axonal loss over time in relation to retinal atrophy, and neurological and radiological abnormalities in MS.
Methods
UNASSIGNED
Patients with relapsing-remitting (RRMS) (
Results
UNASSIGNED
In patients with RRMS compared with controls at baseline, CNFD (
Conclusion
UNASSIGNED
Progressive corneal and retinal axonal loss was identified in patients with MS, especially those with more active disease. CCM may serve as an imaging biomarker of axonal loss in MS.
Identifiants
pubmed: 36776530
doi: 10.1177/17562864221118731
pii: 10.1177_17562864221118731
pmc: PMC9909084
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17562864221118731Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: Drs Ioannis N. Petropoulos, Fatima Al-Shibani, Gulfidan Bitirgen, Georgios Ponirakis, Adnan Khan, Hoda Gad, Ziyad R. Mahfoud, Heba Altarawneh, Muhammad Hassan Rehman, Karen John, Dhabia Al-Merekhi, Pooja George, Ali Ulvi Uca, Ahmet Ozkagnici, Faiza Ibrahim, Reny Francis, Beatriz Canibano, Dirk Deleu, Ahmed El-Sotouhy, Surjith Vattoth, Ahmed Own, Ashfaq Shuaib, Naveed Akhtar and Saadat Kamran declare no conflict of interest. Dr. Rayaz A. Malik is a principal investigator on grants from Proctor and Gamble and Pfizer and has received consulting honoraria for serving on advisory boards for Novo Nordisk, Aventis Pharma, and Proctor and Gamble.
Références
Ann Neurol. 2015 Nov;78(5):801-13
pubmed: 26190464
Ann Clin Transl Neurol. 2015 Dec 28;3(2):88-100
pubmed: 26900579
Ann Neurol. 2018 Dec;84(6):893-904
pubmed: 30294800
Nat Rev Neurol. 2018 Feb;14(2):75-93
pubmed: 29326424
Nat Rev Neurol. 2009 May;5(5):256-66
pubmed: 19488083
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Parkinsonism Relat Disord. 2015 Dec;21(12):1454-60
pubmed: 26578039
Transl Vis Sci Technol. 2020 Dec 21;9(13):37
pubmed: 33384891
Neurology. 2005 Apr 12;64(7):1144-51
pubmed: 15824338
Sci Rep. 2021 Nov 4;11(1):21688
pubmed: 34737384
J Neurol. 2020 Dec;267(12):3541-3554
pubmed: 32621103
Brain. 1997 Mar;120 ( Pt 3):393-9
pubmed: 9126051
Mult Scler Relat Disord. 2018 Jan;19:124-128
pubmed: 29216540
Brain. 2006 Mar;129(Pt 3):606-16
pubmed: 16415308
BMJ Open Diabetes Res Care. 2020 Jun;8(1):
pubmed: 32576561
Diabetes Care. 2015 Jun;38(6):1138-44
pubmed: 25795415
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3677-3681
pubmed: 28727882
J Neurol. 2016 Jul;263(7):1323-31
pubmed: 27142714
J Neuroimaging. 2021 Mar;31(2):401-407
pubmed: 33314460
Invest Ophthalmol Vis Sci. 2012 Feb 21;53(2):825-32
pubmed: 22247457
JAMA Ophthalmol. 2017 Jul 1;135(7):777-782
pubmed: 28570722
Ann Neurol. 2019 May;85(5):618-629
pubmed: 30851125
Cornea. 2020 Oct;39(10):1221-1226
pubmed: 32732697
Diabetologia. 2019 Aug;62(8):1478-1487
pubmed: 31175373
Mult Scler. 2017 Dec;23(14):1847-1853
pubmed: 27811337
Ann Clin Transl Neurol. 2019 Mar 02;6(4):689-697
pubmed: 31019993
N Engl J Med. 2002 Jan 17;346(3):158-64
pubmed: 11796849
Neurol Sci. 2020 Oct;41(10):2893-2904
pubmed: 32333180
Neurology. 2017 Jun 13;88(24):2294-2301
pubmed: 28515269
Diabetes Care. 2020 Aug;43(8):1829-1835
pubmed: 32139385
Lancet Neurol. 2016 May;15(6):574-84
pubmed: 27011339
Brain. 2001 Sep;124(Pt 9):1813-20
pubmed: 11522583
Ann Neurol. 2010 Jun;67(6):749-60
pubmed: 20517936
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO52-BIO60
pubmed: 28475703
Diabetes Care. 2013 Nov;36(11):3646-51
pubmed: 23877983
Brain Pathol. 2013 Jan;23(1):2-12
pubmed: 22612622
PLoS One. 2015 Oct 02;10(10):e0139394
pubmed: 26430773
J Neurol. 2021 May;268(5):1808-1817
pubmed: 33387013
Diabetes Care. 2012 Apr;35(4):821-8
pubmed: 22323412
Ann Clin Transl Neurol. 2019 Jan 19;6(2):222-232
pubmed: 30847355
Invest Ophthalmol Vis Sci. 2014 Apr 03;55(4):2071-8
pubmed: 24569580
Clin Chem. 2015 Dec;61(12):1446-52
pubmed: 26510957
Invest Ophthalmol Vis Sci. 2014 Apr 24;55(5):3195-9
pubmed: 24764058
Exp Eye Res. 2003 May;76(5):521-42
pubmed: 12697417
Curr Eye Res. 2021 Oct;46(10):1452-1459
pubmed: 33734930
Cornea. 2013 May;32(5):e83-9
pubmed: 23172119